Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
A phase 3 trial of Pembrolizumab, Epacadostat, Cetuximab, Cisplatin and Carboplatin in Head and neck squamous cell carcinoma, run by Incyte Corporation, completed.
Overview
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) is a phase 3 interventional study registered as NCT03358472 by Incyte Corporation, with 89 participants recorded, started 2017-12-01 and reaching its primary completion in 2018-07-19. Interventions recorded: Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil. Conditions recorded: Head and Neck Cancer.
Linked to the drug Epacadostat because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialNivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Shares Epacadostat, Incyte, Cisplatin, Carboplatin and the tag pipeline.
- TrialPembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Shares Epacadostat, Incyte, Pembrolizumab and the tag pipeline.
- TrialA Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Shares Cetuximab, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
- TrialA Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Shares Cetuximab, Cisplatin, Carboplatin and the tag pipeline.
- TrialFID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Shares Cetuximab, Head and neck squamous cell carcinoma and the tag pipeline.
- TrialEfficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Shares Cisplatin, Carboplatin, Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
- TrialA Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Shares Carboplatin, Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
- TrialA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Shares Cisplatin, Carboplatin, Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.